Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients ...Middle East

PR Newswire - News
HANGZHOU, China and SHAOXING, China, May 10, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today the Investigational New Drug (IND) application approval of ASC22 (Envafolimab) by U.S. Food and Drug Administration (FDA) for the indication of immune...

Hence then, the article about ascletis announces u s ind approval of asc22 envafolimab for immune restoration functional cure of hiv 1 infected patients was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients )

Apple Storegoogle play

Last updated :

Also on site :